

MS & Skin Integrity:

A provider's primer on pressure ulcers
and other skin issues

Christine Herb, MS, NP-C, CWON
Syracuse VAMC
April 9, 2013

VA MS Centers of Excellence
Call in number: 1.800.767.1750, 43157#
Time: 1-2pm PT, 2-3pm MT, 3-4pm CT, 4-5pm ET

Learning Objectives: At the conclusion of this activity, participants should be able to...

- ⦿ Define and list the National Pressure Ulcer Advisory Panel stages of pressure ulcers developed to improve patient care.
- ⦿ **Identify etiological factors that contribute to patients' risk of pressure ulcers**
- ⦿ List recognized standards of care that aid in the prevention of pressure ulcers
- ⦿ **Discuss injection site problems and prevention strategies associated with MS disease modifying therapies.**

NOTE:

- 1. See slides 35-36 for CEU/CME credit**
- 2. See slide 37 for upcoming calls**

of Veterans with Stage III & IV HAPU per VANOD



CMS estimates cost of hospitalization for Stage III & IV Pressure ulcer at \$43,180.
Slide developed by Suzy Scott-Williams, RN, MS, CWOCN

Beyond Resource Impact: Pain & suffering

? ...!



VHA PU Handbook 2011 ,Pg 23-24

- d. If the Veteran is **bed-confined, a wheelchair user, or requires assistance** to transfer or change position, performing a skin assessment needs to be considered, and educational materials provided on the prevention of pressure ulcers.
- e. Qualified **clinicians need to** consider performing a **complete skin assessment**, if they identify a significant decline in condition or functional status of the Veteran that would contribute to increased risk of pressure ulcers.
- If a new or existing pressure ulcer is identified, the **ulcer needs to be documented** and a prevention or treatment plan initiated or revised to reflect the Veteran's current condition. The provider may request a wound care consult, or other consults deemed appropriate to other service(s).

Definition



The National Pressure Ulcer Advisory Panel (NPUAP) serves as the authoritative voice for improved patient outcomes in pressure ulcer prevention and treatment through public policy, education and research.

- International NPUAP-EPUAP Pressure Ulcer Definition


A pressure ulcer is **localized injury** to the skin and/or underlying tissue usually **over a bony prominence**, as a result of **pressure, or pressure in combination with shear**.

A number of **contributing** or confounding **factors** are also associated with pressure ulcers; the significance of these factors is yet to be elucidated.

How & Where PU develop



Over a boney prominence
or **hard object on soft tissue:**



How long does it take?

- High pressure over relatively short periods


OR

- Low pressures over extended periods of time when tissue tolerance is diminished.

- As little as 2-6 hours!

Anatomic Locations of Pressure Ulcers


1. Sacrum	36.9%
2. Heel	30.3%
3. Ischium (sit bone)	8.0%
4. Elbow	6.9%
6. Trochanter (hip bone)	5.1%
7. Knee	3.0%
8. Scapula (shoulder blade)	2.4%
9. Occiput (back of head)	1.3%




NPUAP Pressure Ulcer Stages

The staging system is a classification tool to document the extent of tissue damage due to pressure. How deep did the tissue loss extend to? It is not to be used to describe any other type of tissue damage or ulceration.


I




II





III



IV



Unstagnable



SDTI
suspected
deep tissue
injury

Suspected Deep Tissue Injury:

Purple or maroon localized area of discolored intact skin or **blood-filled blister** due to damage of underlying soft tissue from pressure and/or shear.

The area may be preceded by tissue that is painful, firm, mushy, boggy, warmer or cooler as compared to adjacent tissue.



Suspected Deep Tissue Injury

Evolution may include a **thin blister over a dark wound bed.**

The wound may further evolve and become covered by thin eschar. **Evolution may be rapid** exposing additional layers of tissue even with optimal treatment.



Suspected Deep Tissue Injury



Stage I

Intact skin with **non-blanchable redness** of a localized area usually over a bony prominence.

Darkly pigmented skin may not have visible blanching; its color may differ from the surrounding area.



Stage II

Partial thickness loss of dermis presenting as a shallow open ulcer with a **red pink wound bed**, without slough.

May also present as an intact or open/ruptured **serum-filled blister**.



Stage III

Full thickness tissue loss.

Subcutaneous fat may be visible but bone, tendon or muscle are not exposed.

Slough may be present but does not obscure the depth of tissue loss.

May include undermining and tunneling.




Stage IV

Full thickness tissue loss with exposed **bone, tendon or muscle.**

Slough or eschar may be present on some parts of the wound bed.

Often include undermining and tunneling.



Unstagnable

Presence of necrotic tissue prevents us from being able to assign a stage.



Other considerations in staging

The depth of a Stage III & IV pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and malleolus do not have (adipose) subcutaneous tissue and Stage III & IV ulcers can be shallow.



Etiology: Pressure vs ?



Etiology: Pressure vs ?



VA Skin Bundle

V

- Veteran's Skin Bundle

A

- Assess Skin and Risk Status^{1,2,3,4}
 - > Risk Assessment on Admission (Braden, SCI, Surgery, medical device)
 - > Inspect skin during care activities (e.g. turning, bathing)

S

- Select Surfaces and Devices to Redistribute/Relieve Pressure^{1,2,3}

K

- Keep Turning and Repositioning^{1,2,3}

I

- Incontinence Management^{1,2,3}

N

- Nutrition and Hydration Assessment and Intervention^{1,2,3,4}

Assessing Risk for PU:

- The Braden Scale score is the total of the subcategory scores.

- > Sensory Perception
- > Moisture
- > Activity
- > Mobility
- > Nutrition
- > Friction and Shear

- Lower score → higher risk. Score 18 or less = at risk for PU development

BRADEN SCALE—For Predicting Pressure Sore Risk

RISK FACTOR	SCORE/DESCRIPTION				DATE OF ASSESS				
	1	2	3	4	1	2	3	4	
SENSORY PERCEPTION Ability to respond meaningfully to pressure-related discomfort	1. COMPLETELY LIMITED —Unresponsive (does not react, blink, or grimace to painful stimuli, due to decreased mental awareness or sedation). ☐ Inflated skin on the palm over front of body part.	2. VERY LIMITED —Responds only to painful stimuli. Cannot demonstrate discomfort except by moaning or restlessness. ☐ Has a sensory apparatus which limits the ability to feel pain or discomfort over 50% of body.	3. SLIGHTLY LIMITED —Responds to verbal commands but cannot always communicate discomfort as needed to be turned. ☐ Has some sensory equipment which limits ability to feel pain or discomfort in 1 or 2 extremities.	4. NO DEFICIT —Responds to verbal commands. Has no sensory deficit noted, would limit ability to feel or move part as required.					
MOISTURE Degree to which skin is exposed to moisture	1. CONSTANTLY MOIST —Skin is kept moist almost constantly by perspiration, urine, etc. Combs to be changed every time patient is moved or turned.	2. OFTEN MOIST —Skin is often but not always moist. Level must be changed at least once a shift.	3. OCCASIONALLY MOIST —Skin is occasionally moist, requiring at least one change approximately once a day.	4. RARELY MOIST —Skin is usually dry, even only requires changing at routine intervals.					
ACTIVITY Degree of physical activity	1. BEDFAST —Confined to bed.	2. CHAIRFAST —Needs to have severely limited or no mobility. Cannot bear own weight and/or must be assisted into chair or wheelchair.	3. WALKS OCCASIONALLY —Walks occasionally during shift but not with great frequency. Must be accompanied by staff or other.	4. WALKS FREQUENTLY —Walks outside the room at least twice a day and walks over at least once every 1 hour during waking hours.					
MOBILITY Ability to change and control body position	1. COMPLETELY IMMOBILE —Does not make any slight changes in body or extremity position without assistance.	2. VERY LIMITED —Makes occasional slight changes in body or extremity position but unable to make frequent or significant changes independently.	3. SLIGHTLY LIMITED —Makes frequent though slight changes in body or extremity position independently.	4. NO LIMITATIONS —Makes major and frequent changes in position without assistance.					
NUTRITION Usual food intake (patients) *NPO: Nothing by mouth. *N: Nothing orally. *TPN: Total parenteral nutrition.	1. VERY POOR —Does not eat a complete meal. Usually eats less than 1/3 of any food offered. Sips (meat or dairy products) per day. Tastes, fluids given. Does not take a fluid (water, supplement). ☐ If NPO: Initial maintained on clear liquids or 1/2 fluid every 3 days.	2. PROBABLY INADEQUATE —Usually eats a complete meal and generally eats only about 1/2 of any food offered. Drinks only 1/2 strength of dairy products or fluid per day. Occasionally will take a dietary supplement. ☐ Needs less than optimum amount of liquid and/or tube feeding.	3. ADEQUATE —Eats own food if most meals. Eats a total of 4 servings of protein meat, dairy products each day. Occasionally will refuse a meal, but will usually take it if reoffered if offered. ☐ If on a tube feeding or TPN: Eats 1/2 or 3/4 of night's, which probably meets most of nutritional needs.	4. EXCELLENT —Eats most of every meal. Spars refuse a meal. Usually eats a total of 4 or more servings of food and dairy products. Occasionally eats between meals. Does not require supplements.					
FRICION AND SHEAR	1. PROBLEM —Requires assistance to move. Complete lifting without sliding against sheets is impossible. Frequent skin abrasions on bed or chair, requiring frequent repositioning with maximum assistance. Supports, cushions, or slings in use to almost constant fashion.	2. POTENTIAL PROBLEM —Moves easily or requires minimum assistance. During a move, skin probably slides to some extent against sheets, chair, cushions, or other devices. Moves relatively good position in chair or bed most of the time but occasionally slides down.	3. NO APPARENT PROBLEM —Moves on bed and/or chair independently and has sufficient muscle strength to sit up completely during move. Remains good position in bed or chair at all times.						
TOTAL SCORE	Total score of 12 or less represents HIGH RISK								
ASSESS	DATE	EVALUATOR SIGNATURE/TITLE	ASSESS	DATE	EVALUATOR SIGNATURE/TITLE				
1	/ /		3	/ /					
2	/ /		4	/ /					
NAME-Last	First	Middle	Ascending #/Physian	Room No.	Room/Bed				

Form 3999 (Rev. 06/2006) © 1988, 2006, 2007, 2008
Source: Barbara Braden and Nancy Bergstrom
Copyright, 1988. Reprinted with permission.
BRADEN SCALE

Prevention correlated w/ low scoring Risk factors:

- Skin Care
- Pressure Redistribution
- Nutritional Interventions
- Incontinence Care

Pressure Ulcer Prevention

Turn **Q2 hours** (while in bed)
or **Q hour** (up in chair)




“The Rule of 30”

Side lying position @ 30 degree angle
(lays back onto pillow & ONE incontinent pad under patient)



Shows 30° side lying position using pillows and foam wedge

Be sure pillow is **ABOVE SACRUM**



Hipbone
30°
Tailbone
Fleshy part of buttocks


30° laterally inclined position with proper pillow positioning

“Head down-Heels UP”



Elevate heels **OFF** bed with pillow @ calves so **NO HEEL CONTACT**

Keep head of bed **LOW**
(30 degrees or LOWER unless contraindicated)



Proper positioning in chair with **EFFECTIVE CUSHION**
(NO Pads over cushions!)




(Diagrams from "Pressure Ulcers", by Maklebust, 1996)

Position – Position – Position!

IS the  to prevention.

- ✓ Upright seating w/ effective seat cushion




Reposition **every 1 hr**

- ✓ Positioning w/ pillows, foam wedges



Reposition **every 2 hrs**

Therapeutic dynamic **off-loading** bed & seat surfaces are essential



Ineffective pressure relief devices



Potentially effective or harmful

Every device applied to the body has the potential of causing skin damage



Sometimes
simple
solutions
are best.



**Float
heels!**

Injection Site Reactions

Disease modulating Treatment

- ❖ Localized erythema and/or hives
- ❖ Lipoatrophy
- ❖ Necrosis

Injection Site Reactions Beta Interferon

31



Slide developed by Mary Fitzpatrick, BSN, MPH, ANP, MSCN

Glatiramer Injection Site Reactions

32



Slide developed by Mary Fitzpatrick, BSN, MPH, ANP, MSCN

Prevent or minimize site reactions

- ✓ Monitoring sites & catch problems early
 - ✓ Proper skin cleansing & skin warming
 - ✓ Site rotation (use map or log book)
 - ✓ Proper needle length for sc vs IM & body type
 - ✓ Dry needle tip
 - ✓ Consider auto injectors
 - ✓ Follow proper injection procedure (not too much force)
 - ✓ Avoid sun exposure
- ❖ **Seek wound specialist** for severe reactions involving necrosis



Thank you!

Questions?

For Credit:

- You should be pre-registered for this webinar. If not, contact Heather.Holshouser@va.gov
- Registered participants: Access the TMS website with your user ID and password. Follow the TMS guidelines for this webinar sent to you via email.

For CEUs:

To Print an Accredited Certificate:

- Hover over the item in TMS under Completed Work
- Click “View Details”
- In the Completed Work Details screen, scroll down to the Accreditation Details
- Click the “Print Accreditation Certificate” button next to the accreditation needed

Upcoming Calls & Satellite Event:

- ◎ **May 14** – Optic Neuritis: A Comparison in MS and NMO
 - > Jane Chan, MD, neuro-ophthalmologist, Reno VA
- ◎ **June 12** – Bladder & Bowel satellite broadcast
 - > Drs. Peter Gorman, Nina Davis and Heidi Maloni
- ◎ **June 11** – Updates on Oral DMTs (admin call)
 - > Chris Bever, MD – MSCoE Director-East
- ◎ **July 9** – Rural Health: Delivering Comprehensive MS Care
 - > Paul Hoffman, MD, neurologist, Gainesville VA